RAPP (Rapport Therapeutics) Preferred Dividends : $0.00 Mil (TTM As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Rapport Therapeutics Preferred Dividends?

Preferred dividend is a dividend that is accrued and paid on a company's preferred shares. Rapport Therapeutics's preferred dividends for the three months ended in Sep. 2024 was $0.00 Mil. Its preferred dividends for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00 Mil.

Rapport Therapeutics Preferred Dividends Historical Data

The historical data trend for Rapport Therapeutics's Preferred Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rapport Therapeutics Preferred Dividends Chart

Rapport Therapeutics Annual Data

Trend

Dec22

Dec23

Preferred Dividends

Rapport Therapeutics Quarterly Data
	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Preferred Dividends	Get a 7-Day Free Trial			-	-	-	-	-

Rapport Therapeutics Preferred Dividends Calculation

A dividend that is accrued and paid on a company's preferred shares.

Rapport Therapeutics (NAS:RAPP) Preferred Dividends Explanation

In the event that a company is unable to pay all dividends, claims to preferred dividends take precedence over claims to dividends that are paid on common shares.

Preferred Dividends for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Rapport Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rapport Therapeutics Inc (NAS:RAPP) » Definitions » Preferred Dividends

Comparable Companies

Traded in Other Exchanges

N/A

Address

1325 Boylston Street, Suite 401, Boston, MA, USA, 02215

Website

https://www.rapportrx.com

Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.